SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Preprint
- 17 July 2020
- preprint
- other
- Published by Cold Spring Harbor Laboratory
Abstract
SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality and longevity of the antibody response to the virus remain unanswered. Here we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein, based on a dataset of 19,860 individuals screened at Mount Sinai Health System in New York City. We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody responses and that these titers are stable for at least the near-term future.One Sentence SummaryAntibody responses induced by natural mild-to-moderate SARS-CoV-2 infection are robust, neutralizing and are stable for at least 3 months.Keywords
Other Versions
- Published version: Version Science, 370, preprints
This publication has 23 references indexed in Scilit:
- Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreakNature Communications, 2020
- Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis UnitJama-Journal Of The American Medical Association, 2020
- Serology assays to manage COVID-19Science, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- A serological assay to detect SARS-CoV-2 seroconversion in humansNature Medicine, 2020
- Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City regionPublished by Cold Spring Harbor Laboratory ,2020
- SARS-CoV-2 Vaccines: Status ReportImmunity, 2020
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronavirusesNature Microbiology, 2020
- High neutralizing antibody titer in intensive care unit patients with COVID-19Emerging Microbes & Infections, 2020
- Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike VariantsPLoS Medicine, 2006